Cantor Fitzgerald Forecasts RCUS FY2025 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Arcus Biosciences in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Watsek expects that the company will post earnings of ($5.29) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.20) per share.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.06. Arcus Biosciences had a negative net margin of 102.66% and a negative return on equity of 45.59%. The firm had revenue of $48.00 million during the quarter, compared to analysts’ expectations of $38.95 million. During the same quarter last year, the business earned ($0.94) earnings per share. The business’s revenue for the quarter was up 50.0% compared to the same quarter last year.

Several other research analysts also recently issued reports on the company. HC Wainwright reaffirmed a “neutral” rating and set a $20.00 price target on shares of Arcus Biosciences in a research note on Wednesday, November 6th. Barclays boosted their price target on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Wedbush reiterated an “outperform” rating and set a $36.00 target price on shares of Arcus Biosciences in a research report on Thursday, November 7th. Finally, Wells Fargo & Company assumed coverage on shares of Arcus Biosciences in a report on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 target price for the company. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Arcus Biosciences currently has an average rating of “Buy” and an average price target of $34.00.

Arcus Biosciences Price Performance

RCUS stock opened at $13.41 on Wednesday. The firm has a 50 day moving average of $15.40 and a 200-day moving average of $15.92. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -4.26 and a beta of 0.87. Arcus Biosciences has a 12-month low of $13.40 and a 12-month high of $20.31. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08.

Insider Activity

In other news, CFO Robert C. Goeltz II sold 3,594 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the transaction, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at approximately $902,070. The trade was a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 12.30% of the company’s stock.

Institutional Investors Weigh In On Arcus Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Arcus Biosciences by 2.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company’s stock worth $471,000 after purchasing an additional 843 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Arcus Biosciences by 2.6% in the third quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company’s stock valued at $668,000 after buying an additional 1,117 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Arcus Biosciences by 7.7% during the second quarter. The Manufacturers Life Insurance Company now owns 29,858 shares of the company’s stock valued at $455,000 after buying an additional 2,123 shares in the last quarter. Handelsbanken Fonder AB lifted its holdings in Arcus Biosciences by 15.5% during the 3rd quarter. Handelsbanken Fonder AB now owns 22,300 shares of the company’s stock worth $341,000 after buying an additional 3,000 shares during the last quarter. Finally, Point72 Hong Kong Ltd acquired a new position in shares of Arcus Biosciences in the 3rd quarter worth approximately $47,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.